Indo Us Bio-Tech Q2 Loss Hits Rs 3.67 Crore

Revenue for the quarter stood at Rs 15.05 crore, while net loss reached Rs 3.67 crore.

Reader Takeaway: Sequential revenue growth failed to offset profitability pressures, pushing the company into a net loss for Q2.

What just happened

Indo Us Bio-Tech Ltd reported a net loss of Rs 3.67 crore for the quarter ending September 30, 2026. This marks a significant downturn from the Rs 3.46 crore profit reported in the corresponding quarter last year. The company's basic and diluted Earnings Per Share (EPS) also fell into negative territory at (1.83) for the period.

Why this matters

The transition from profitability to a net loss highlights operational headwinds for the agricultural biotech player. Despite a slight sequential revenue improvement—growing from Rs 13.00 crore in the June 2026 quarter to Rs 15.05 crore in the September 2026 quarter—the overall year-on-year revenue contraction from Rs 30.85 crore reflects ongoing demand or supply-side challenges.

Audit and Governance

The board of directors approved the unaudited financial results on October 30, 2026, following a review by the audit committee. Statutory auditors have issued an unmodified opinion on the financials, and the company confirmed that there were zero unresolved investor complaints at the end of the quarter.

What to track next

Investors should monitor the company's efforts to stabilize its revenue growth and recover margins. Sustained losses in upcoming quarters could pressure the company's capital allocation and valuation. Market participants will likely look for management commentary on the underlying reasons for the sharp year-on-year decline in sales volume.